PL1923073T3 - Leczenie kombinacyjne z inhibitorem PDE-5 - Google Patents

Leczenie kombinacyjne z inhibitorem PDE-5

Info

Publication number: PL1923073T3
Authority: PL; Poland
Prior art keywords: inhibitor; portal hypertension; prevent; portal; treat
Prior art date: 2003-06-06

Application number

PL06025229T

Other languages

English (en)

Polish (pl)

Inventor

Wolfgang Kreisel

Deibert Peter

Original Assignee

Univ Freiburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-06

Filing date

2004-06-03

Publication date

2012-02-29

2004-06-03 Application filed by Univ Freiburg filed Critical Univ Freiburg

2012-02-29 Publication of PL1923073T3 publication Critical patent/PL1923073T3/pl

Links

229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 5
239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 5
229940079593 drug Drugs 0.000 title abstract 2
239000003814 drug Substances 0.000 title abstract 2
208000007232 portal hypertension Diseases 0.000 abstract 6
230000017531 blood circulation Effects 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
210000003240 portal vein Anatomy 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 2
206010003445 Ascites Diseases 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
206010062070 Peritonitis bacterial Diseases 0.000 abstract 1
230000001668 ameliorated effect Effects 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002008 hemorrhagic effect Effects 0.000 abstract 1
230000002440 hepatic effect Effects 0.000 abstract 1
208000007386 hepatic encephalopathy Diseases 0.000 abstract 1
201000004515 hepatopulmonary syndrome Diseases 0.000 abstract 1
201000011200 hepatorenal syndrome Diseases 0.000 abstract 1
230000001553 hepatotropic effect Effects 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL06025229T 2003-06-06 2004-06-03 Leczenie kombinacyjne z inhibitorem PDE-5 PL1923073T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10325813A DE10325813B4 (de)	2003-06-06	2003-06-06	Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP06025229A EP1923073B1 (de)	2003-06-06	2004-06-03	Kombinationsmedikation mit PDE-5-Inhibitor
EP04739573A EP1635838B1 (de)	2003-06-06	2004-06-03	Phosphodiesterase-5-inhibitoren zur prophylaxe und/oder therapie der portalen hypertonie

Publications (1)

Publication Number	Publication Date
PL1923073T3 true PL1923073T3 (pl)	2012-02-29

Family

ID=33494881

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL06025229T PL1923073T3 (pl)	2003-06-06	2004-06-03	Leczenie kombinacyjne z inhibitorem PDE-5
PL04739573T PL1635838T3 (pl)	2003-06-06	2004-06-03	Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL04739573T PL1635838T3 (pl)	2003-06-06	2004-06-03	Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego

Country Status (14)

Country	Link
US (1)	US9278097B2 (es)
EP (2)	EP1635838B1 (es)
JP (3)	JP4557970B2 (es)
KR (2)	KR101233828B1 (es)
CN (1)	CN1871010B (es)
AT (2)	ATE361074T1 (es)
CY (2)	CY1107707T1 (es)
DE (2)	DE10325813B4 (es)
DK (2)	DK1923073T3 (es)
ES (2)	ES2287740T3 (es)
PL (2)	PL1923073T3 (es)
PT (2)	PT1635838E (es)
SI (2)	SI1923073T1 (es)
WO (1)	WO2004108062A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002089808A1 (de) *	2001-05-09	2002-11-14	Bayer Healthcare Ag	Neue verwendung von 2-phenyl-substituierten imidazotriazinonen
DE10232113A1 (de) *	2002-07-16	2004-01-29	Bayer Ag	Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102004023069A1 (de) *	2004-05-11	2005-12-08	Bayer Healthcare Ag	Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) *	2004-08-06	2006-03-16	Bayer Healthcare Ag	Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) *	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de)	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
PT1888074E (pt) *	2005-06-10	2012-03-01	Dong A Pharm Co Ltd	Agente para a prevenção e tratamento de doenças do fígado contendo um derivado de pirazolopirimidina
JP2009509984A (ja) *	2005-09-29	2009-03-12	バイエル・ヘルスケア・アクチェンゲゼルシャフト	泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US8512258B2 (en) *	2005-11-11	2013-08-20	Exalenz Bioscience Ltd.	Breath test device and method
WO2008151734A1 (en) *	2007-06-13	2008-12-18	Bayer Schering Pharma Aktiengesellschaft	Pde inhibitors for the treatment of hearing impairment
WO2014088326A1 (ko)	2012-12-04	2014-06-12	주식회사 아리바이오	포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
US20160317542A1 (en)	2013-12-09	2016-11-03	Respira Therapeutics, Inc.	Pde5 inhibitor powder formulations and methods relating thereto
US11576609B2 (en)	2017-06-30	2023-02-14	Georgia State University Research Foundation, Inc.	Noninvasive methods for detecting liver fibrosis
CA3023014C (en) *	2017-11-06	2023-09-26	Stalicla Sa	Pharmaceutical composition for treatment of autism
CN110811593A (zh) *	2019-11-07	2020-02-21	天津中医药大学第二附属医院	一种高血压中医证型采取肝血流动力学特点的判别方法
KR20240117491A (ko)	2023-01-25	2024-08-01	주식회사 아리바이오	포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2882843B2 (ja) *	1990-03-28	1999-04-12	日本化薬株式会社	門脈圧亢進症改善剤
GB9311920D0 (en)	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
US5973011A (en) *	1994-03-30	1999-10-26	Isis Pharma Gmbh	Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
IL144156A0 (en)	1999-01-20	2002-05-23	Dresden Arzneimittel	Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments
DE19961302A1 (de) *	1999-12-18	2001-06-21	Dresden Arzneimittel	Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
AU3210500A (en) *	1999-01-22	2000-08-07	Selectus Pharmaceuticals, Inc.	Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence
US6087362A (en)	1999-03-16	2000-07-11	Pentech Pharmaceuticals, Inc.	Apomorphine and sildenafil composition
US20010003120A1 (en) *	1999-05-14	2001-06-07	M. D. Robert Hines	Method for treating erectile dysfunction
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
IL139073A0 (en)	1999-10-21	2001-11-25	Pfizer	Treatment of neuropathy
TWI224966B (en)	1999-11-02	2004-12-11	Pfizer	Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
US20020103117A1 (en)	2000-02-03	2002-08-01	Ralph Knoell	Use of protein kinase-inhibitor-alpha
DE10004858A1 (de) *	2000-02-03	2001-08-16	Schering Ag	Verwendung von Proteinkinase-Inhibitor-alpha
US6476037B1 (en)	2000-03-23	2002-11-05	The Regents Of The University Of California	L-arginine and phosphodiesterase (PDE) inhibitor synergism
MXPA03001717A (es)	2000-08-30	2003-09-22	Lilly Icos Llc	METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
US20020028764A1 (en) *	2000-09-04	2002-03-07	Aarhus Amt.	Treatment of acute and chronic liver disease
CA2426674A1 (en)	2000-10-25	2002-05-02	Takeda Chemical Industries, Ltd.	Agent for preventing or treating portal hypertension
JP2002201128A (ja) *	2000-10-25	2002-07-16	Takeda Chem Ind Ltd	門脈圧亢進症予防・治療剤
HUP0302987A2 (hu) *	2001-01-31	2003-12-29	Merck Patent Gmbh	Pirazolo [4,3-d] pirimidinszármazékokat vagy tienopirimidinszármazékokat és nitrátvegyületeket tartalmazó gyógyászati készítmények
MXPA03006936A (es) *	2001-02-02	2003-11-18	Pfizer	Tratamiento de diabetes mellitus.
JP2004525890A (ja)	2001-02-02	2004-08-26	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
US6338862B1 (en) *	2001-03-26	2002-01-15	Sarfaraz K Niazi	Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
BR0210915A (pt)	2001-06-08	2004-06-08	Sod Conseils Rech Applic	Análogos quiméricos de somatostatina-dopamina
LV12979B (en) *	2001-09-07	2003-05-20	Ivars Kalvins	Pharmaceutical composition

2003
- 2003-06-06 DE DE10325813A patent/DE10325813B4/de not_active Expired - Fee Related
2004
- 2004-06-03 US US10/559,694 patent/US9278097B2/en not_active Expired - Fee Related
- 2004-06-03 PL PL06025229T patent/PL1923073T3/pl unknown
- 2004-06-03 EP EP04739573A patent/EP1635838B1/de not_active Expired - Lifetime
- 2004-06-03 AT AT04739573T patent/ATE361074T1/de active
- 2004-06-03 CN CN2004800225122A patent/CN1871010B/zh not_active Expired - Fee Related
- 2004-06-03 PT PT04739573T patent/PT1635838E/pt unknown
- 2004-06-03 EP EP06025229A patent/EP1923073B1/de not_active Expired - Lifetime
- 2004-06-03 KR KR1020117030506A patent/KR101233828B1/ko not_active Expired - Fee Related
- 2004-06-03 AT AT06025229T patent/ATE525074T1/de active
- 2004-06-03 WO PCT/EP2004/006014 patent/WO2004108062A2/de not_active Ceased
- 2004-06-03 DE DE502004003694T patent/DE502004003694D1/de not_active Expired - Lifetime
- 2004-06-03 DK DK06025229.3T patent/DK1923073T3/da active
- 2004-06-03 SI SI200431750T patent/SI1923073T1/sl unknown
- 2004-06-03 ES ES04739573T patent/ES2287740T3/es not_active Expired - Lifetime
- 2004-06-03 PL PL04739573T patent/PL1635838T3/pl unknown
- 2004-06-03 PT PT06025229T patent/PT1923073E/pt unknown
- 2004-06-03 JP JP2006508268A patent/JP4557970B2/ja not_active Expired - Fee Related
- 2004-06-03 SI SI200430378T patent/SI1635838T1/sl unknown
- 2004-06-03 ES ES06025229T patent/ES2374085T3/es not_active Expired - Lifetime
- 2004-06-03 DK DK04739573T patent/DK1635838T3/da active
2005
- 2005-12-05 KR KR1020057023300A patent/KR101176110B1/ko not_active Expired - Fee Related
2007
- 2007-08-01 CY CY20071101024T patent/CY1107707T1/el unknown
2009
- 2009-07-24 JP JP2009172766A patent/JP5757677B2/ja not_active Expired - Fee Related
2010
- 2010-05-12 JP JP2010109855A patent/JP5631053B2/ja not_active Expired - Fee Related
2011
- 2011-10-07 CY CY20111100960T patent/CY1111918T1/el unknown

Also Published As

Publication number	Publication date
EP1923073B1 (de)	2011-09-21
DE10325813B4 (de)	2007-12-20
PL1635838T3 (pl)	2007-09-28
DE10325813A1 (de)	2005-01-05
KR20120024807A (ko)	2012-03-14
US20070004744A1 (en)	2007-01-04
WO2004108062A2 (de)	2004-12-16
JP2009280602A (ja)	2009-12-03
ES2374085T3 (es)	2012-02-13
DK1923073T3 (da)	2011-10-17
KR20060031614A (ko)	2006-04-12
SI1635838T1 (sl)	2007-10-31
EP1635838B1 (de)	2007-05-02
ES2287740T3 (es)	2007-12-16
EP1635838A2 (de)	2006-03-22
EP1923073A3 (de)	2008-07-09
CY1111918T1 (el)	2015-11-04
ATE361074T1 (de)	2007-05-15
CN1871010B (zh)	2010-05-26
SI1923073T1 (sl)	2011-11-30
KR101176110B1 (ko)	2012-08-22
DK1635838T3 (da)	2007-09-10
KR101233828B1 (ko)	2013-02-14
CY1107707T1 (el)	2013-04-18
JP2006527177A (ja)	2006-11-30
JP5631053B2 (ja)	2014-11-26
EP1923073A2 (de)	2008-05-21
US9278097B2 (en)	2016-03-08
JP2010195821A (ja)	2010-09-09
PT1635838E (pt)	2007-08-10
PT1923073E (pt)	2011-10-04
JP4557970B2 (ja)	2010-10-06
DE502004003694D1 (de)	2007-06-14
JP5757677B2 (ja)	2015-07-29
WO2004108062A3 (de)	2005-03-10
CN1871010A (zh)	2006-11-29
ATE525074T1 (de)	2011-10-15

Publication	Publication Date	Title
CY1111918T1 (el)	2015-11-04	Συνδυασμενη φαρμακευτικη αγωγη με αναστολεα της φωσφωδιεστερασης-5
BR0108452A (pt)	2003-04-01	Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
EP1500403A4 (en)	2008-09-17	MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
WO2003035009A3 (en)	2004-03-18	Treatment of acute myeloid leukemia with indolinone compounds
NO20006484D0 (no)	2000-12-19	Pro-legemidler av dipeptidyl peptidase IV-inhibitorer
EP1541551A8 (en)	2005-11-09	2-cyano-4-fluoropyrrolidine derivative or its salt
TR200000129T2 (tr)	2000-07-21	Yepyeni spiroazabisiklik heterosiklik bileşikler.
AU2002351753A8 (en)	2003-07-30	Combined use of a glp-1 compound and a modulator of diabetic late complications
IL160420A0 (en)	2004-07-25	Treating or preventing diabetes with cannabidiol
NO20063572L (no)	2003-02-24	Kinazolinditosylatsalt forbindelser
EP1389988A4 (en)	2005-03-23	CATHETER SYSTEM WITH MOVABLE HEAT EXCHANGER
WO2004037205A8 (en)	2005-04-14	LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL
EP1671649A4 (en)	2007-05-02	MEANS FOR THE TREATMENT OF DIABETES
DE602007008385D1 (de)	2010-09-23	Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris
WO2002030867A3 (en)	2002-07-25	Drugs for diabetes
ATE315558T1 (de)	2006-02-15	Verbindungen mit cytochrom p450ra1 hemmenden aktivität
NO20026251L (no)	2002-12-27	Ventilanordning med middels bruddtrykk
PT1007055E (pt)	2004-06-30	Utilizacao de amifostina
WO2005097103A3 (en)	2006-08-10	Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
DK1037629T3 (da)	2005-03-07	Kombination af et retinsyremetabolismeblokerende middel og en tocopherol
WO2003004046A3 (en)	2003-03-20	Use of xaa-pro peptidases for the treatment of substance p-related disorders
AU2003223528A1 (en)	2003-10-27	Treatment for type 1 diabetes before and after expression of predisposition markers.
WO2002017905A3 (en)	2002-05-16	Treatment of burns
IS6017A (is)	2001-07-20	Aðferð til meðhöndlunar á höfuðverk
WO2006124544A3 (en)	2007-09-07	Use of tyrosine kinase inhibitors in the treatment of metabolic disorders